Ionfinity is an expert in commercializing emergent technologies via strong partnerships with the U.S. Department of the Army, the Department of the Navy, and the Air Force (USAF). A subsidiary of the VIASPACE family, Ionfinity is a pioneer in bleeding-edge Mass Spectrometry (MS), a technology which allows for real-time sampling and analysis of trace amounts of a substance.

Ionfinity enjoys a continuous relationship of development with the National Aeronautical and Space Administration (NASA), NASA’s Jet Propulsion Laboratory (JPL), and the California Institute of Technology (Caltech). Ionfinity also maintains partner programs with General Dynamics Corp., Imaginative Technologies LLC., and Sionex Corporation.

Ionfinity is currently developing applications of its proprietary “soft-ionization” technology, capitalizing on a vast wealth of experience in miniaturization, to produce truly next generation MS sensors capable of “sniffing” molecular concentrations of a substance in the parts-per-trillion to sub-parts-per-billion range within

Oxygen Biotherapeutics now has a clinical development pipeline which includes seven indications for Oxycyte(TM) emulsion. Oxycyte is the Company’s perfluorocarbon (PFC) therapeutic oxygen carrier. The new Oxycyte pipeline includes: Traumatic Brain Injury, Carbon Monoxide Poisoning, Surgical Iatrogenic Air Embolism, Spinal Cord Injury, Organ Preservation, Decompression Sickness, and Sickle Cell Crisis.

The company has also reported that its topical pipeline includes six additional indications in development for the Oxycyte Gel. The first use of the Dermacyte Gel is for a cosmetic line that is now available for pre-orders via the BuyDermacyte.com website, with product shipment expected in about four weeks. Other uses include treatment for Wounds, Burns, Acne, Rosacea, Cell Treatment after Radiation Therapy, and Erectile Dysfunction. Oxygen Biotherapeudics is also working on two additional uses for Oxycyte Compounds, including a ventilation device called VitaVent and a Deep Immersion Fluorocarbon Treatment for severe burns.

Oxygen Biotherapeutics CEO Chris Stern commented on the